


PRODUCT INFORMATION



Tanomastat

Item No. 19258

CAS Registry No.: 179545-77-8
Formal Name: 4'-chloro-γ-oxo-αS-
[(phenylthio)methyl]-[1,1'-
biphenyl]-4-butanoic acid
Synonym: BAY 12-9566
MF: C₂₃H₁₉ClO₃S
FW: 410.9
Purity: ≥98%
UV/Vis.: λ_{max}: 285 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Tanomastat is supplied as a crystalline solid. A stock solution may be made by dissolving the tanomastat in the solvent of choice, which should be purged with an inert gas. Tanomastat is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of tanomastat in ethanol is approximately 12 mg/ml and approximately 25 mg/ml in DMSO and DMF.

Tanomastat is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, tanomastat should first be dissolved in DMF and then diluted with the aqueous buffer of choice. Tanomastat has a solubility of approximately 0.5 mg/ml in a 1:1 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

Tanomastat is an inhibitor of matrix metalloproteinase-2 (MMP-2), MMP-3, and MMP-9 (K_i s = 11, 143, and 301 nM, respectively).¹ It is selective for MMP-2, -3, and -9 over MMP-1 and MMP-13 (K_i s = 5,000 and 1,470 nM, respectively). Tanomastat (15 μM) inhibits VEGF- and FGF-induced tubule formation in human umbilical vein endothelial cells (HUVECs).² It reduces tumor growth and the number of pulmonary metastases in an MDA-MB-435 orthotopic mouse model of breast cancer when administered at a dose of 100 mg/kg. Tanomastat (50 mg/kg) decreases disease severity in a rat model of adjuvant-induced arthritis.³

References

1. Leung, D., Abbenante, G., and Fairlie, D.P. Protease inhibitors: Current status and future prospects. *J. Med. Chem.* **43**(3), 305-341 (2000).
2. Nozaki, S., Sissons, S., Chien, D.-S., *et al.* Activity of biphenyl matrix metalloproteinase inhibitor BAY 12-9566 in a human breast cancer orthotopic model. *Clin. Exp. Metastasis* **20**(5), 407-412 (2003).
3. Hamada, T., Arima, N., Shindo, M., *et al.* Suppression of adjuvant arthritis of rats by a novel matrix metalloproteinase-inhibitor. *Br. J. Pharmacol.* **131**(8), 1513-1520 (2000).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/19/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM